Skip to content
Evigrade
ModerateBiguanides. Oral antihyperglycemic agents×Antianginal – late sodium current inhibitor

Updated · Methodology

Mechanism

The kidneys eliminate metformin with the help of organic cation transporter 2 (OCT2), and OCT2 inhibitors, ranolazine among them, may slow its elimination and raise metformin levels (metformin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In people with type 2 diabetes, ranolazine 500 mg twice daily increased metformin exposure 1.4-fold and 1000 mg twice daily 1.8-fold (ranolazine SmPC, European Medicines Agency, EMA). Accumulation of metformin may increase the risk of lactic acidosis (metformin label, US Food and Drug Administration, FDA).

Symptoms

Metformin-associated lactic acidosis is very rare but serious. It presents with acidotic breathlessness, abdominal pain, muscle cramps, weakness and low body temperature, followed by coma. Blood tests show pH below 7.35 and lactate above 5 mmol/L (metformin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). It occurs most often with acute worsening of renal function, cardiorespiratory disease or sepsis (AEMPS). The onset can be subtle, with malaise, muscle pain, breathing difficulty and somnolence. Severe acidosis can bring low blood pressure and bradyarrhythmias that resist treatment (metformin label, US Food and Drug Administration, FDA).

Management

The documents do not prohibit the combination. With inhibitors of organic cation transporter 2 (OCT2), ranolazine among them, use metformin with caution, especially in renal impairment, and adjust its dose if needed (metformin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US metformin label says to consider the benefits and risks of the combination (metformin label, US Food and Drug Administration, FDA). With ranolazine 1000 mg twice daily, the US ranolazine label limits metformin to 1700 mg a day and says to monitor blood glucose and the risks of high metformin exposure. With ranolazine 500 mg twice daily, the label reports no significant increase in metformin exposure (ranolazine label, FDA). The 1000 mg twice-daily ranolazine dose is not used in Europe: the maximum there is 750 mg twice daily, and the European SmPC gives only the exposure figures for metformin, with no dose advice (ranolazine SmPC, European Medicines Agency, EMA). Assess the glomerular filtration rate (GFR) before starting metformin and regularly afterwards. Metformin is contraindicated if GFR is below 30 mL/min. Stop it temporarily in conditions that impair renal function (AEMPS). Monitor renal function regularly during ranolazine treatment as well (EMA). If lactic acidosis is suspected, stop metformin at once and treat the patient in hospital (metformin SmPC and label, AEMPS and FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Metformin

Other interactions with Ranolazine